U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07008794) titled 'Effect of Genetic Variation on Efficacy and Safety of Lipid-Lowering Drugs' on May 20.
Brief Summary: The primary end point was to reduce LDL-C levels by at least 50%, while the secondary end point was to achieve an LDL-C level below 55 mg/dL. The incidence and specifics of side effects and laboratory abnormalities were recorded throughout the follow-up period to evaluate safeguarding. Liver function tests were performed at baseline and 12 weeks later. Any muscle-related complaints were noted at baseline and during the 12-week sessions. CK total and Hba1c were also assessed
Study Start Date: April 01, 2022
Study Type: OBSERVATIONAL...